(This is Part 2 of the article: "The Best Charts in the Book Are All in Breakout Mode")
NEW YORK (Real Money) -- The second-strongest group doesn't jibe with the strongest: Health care. You should be a hard seller of these stocks if rates are going higher. Someone's wrong here.
Or, it is just possible that portfolio managers never lose their ardor for stocks like Valeant (VRX), Bristol-Myers Squibb (BMY) and Abbott Laboratories (ABT) on the drug side, Aetna (AET), Anthem (ANTM) and Cigna (CI), in the health maintenance group, Cardinal (CAH) and the ever-so-loved McKesson (MCK), in the cost containers, HCA (HCA) for hospitals and Regeneron (REGN) in biotech, although I think that Gilead's (GILD) finally making its move.
There's always one beloved device company, and the one that's been seized on in this environment, now surpassing Edwards (EW) for love, is St. Jude Med (STJ), which showed me on "Mad Money" its incredibly small heart device, which is now shipping in volume and will be huge.
I don't know if portfolio managers will ever leave these stocks, no matter how high rates go -- something I didn't think I would ever write, but it's been so long since a rate hike, who knows how well they will behave?